Erratum {#Sec1}
=======

After publication of the original article \[[@CR1]\], the authors noticed that there were errors in the caption of Fig. 3, and the y-axis of Fig. [6](#Fig1){ref-type="fig"} itself.Fig. 6Mean CNS-LS Scores Across DM/Q Studies for PBA Secondary to Diverse Neurologic Conditions. \*DM/Q 30/30 mg twice daily; †DM/Q 20/10 mg twice daily. ‡Improvement from baseline in mean CNS-LS (SE). 99-AVR-102 (4 week study comparing DM/Q to DM or Q monotherapy): End of study is the mean of the CNS-LS scores for Days 15 and 29; *P* = 0.001 vs. dextromethorphan comparator and *P* \< 0.001 vs quinidine comparator. 02-AVR-106 (12 week DBPC study): End of study is the mean of the CNS-LS scores on Days 15, 29, 57, and 85; *P* \< 0.0001 vs. placebo. 07-AVR-123 (12 week DBPC study): End of study is at Week 12 intent to treat; *P* \< 0.05 vs. placebo. PRISM II: End of study is at Day 90/Final Visit; *P* \< 0.001 vs. baseline in all 3 cohorts. ALS = amyotrophic lateral sclerosis; CNS-LS = Center for Neurologic Study--Lability Scale; DM/Q = dextromethorphan/quinidine; MS = multiple sclerosis; PBA = pseudobulbar affect; TBI = traumatic brain injury; SE = standard error

The following statement should not have been included in the caption of Fig. 3: "CNS-LS scores were not normalized." The CNS-LS is a rank-order scale, and is not normalized. This statement was included erroneously and the authors intended on removing it prior to resubmission, but this was unfortunately overlooked.

Similarly, the y-axis within Fig. [6](#Fig1){ref-type="fig"} was mislabelled. The CNS-LS scale ranges from 7 to 35, so the y-axis for Fig. [6](#Fig1){ref-type="fig"} should start at a base score of 7 and not zero. The correct and updated version of Fig. [6](#Fig1){ref-type="fig"}, in which the data presented remain accurate and are unchanged, is published in this erratum.

The online version of the original article can be found under doi:10.1186/s12883-016-0609-0.
